Scarica l'app Stockscreener
0.99
10.81%
-0.12
Anebulo Pharmaceuticals Inc Borsa (ANEB) Ultime notizie
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 9.8% – Should You Sell? - Defense World
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 - Investing.com India
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 - Investing.com India
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates - Defense World
Anebulo Pharma Secures $1.9M NIDA Grant for Cannabis Toxicity Treatment Development | ANEB Stock News - StockTitan
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com UK
Exxaro Resources (OTCMKTS:EXXAY) Share Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
Short Interest in Janone Inc. (NASDAQ:ALTS) Expands By 10.2% - Defense World
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Anebulo Pharmaceuticals Updates Corporate Presentation - TipRanks
Anebulo To Report Acute Cannabinoid Intoxication Trial Data In June - RTTNews
Benchmark maintains Speculative Buy on Anebulo stock By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals (NASDAQ:ANEB) Earns "Speculative Buy" Rating from Benchmark - MarketBeat
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 27.7% in September - Defense World
Anebulo Pharmaceuticals reports Q4 EPS (5c) vs. (10c) last year - TipRanks
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates - Business Wire
Njabulo Blom set to boost Kaizer Chiefs midfield - FarPost
Kirkland Advises Luminate Capital Partners on its Investment in AbsenceSoft - Legal Desire News Network
Amway marks “Amway Health Run 2024” to celebrate Nutrilite’s 90th anniversary - Nation Thailand
Market Movers Monday: KAVL, PRSO, TGL, PNPNF, NVVE Surge on Breaking Developments - openPR
'Survival instinct kicked in': Survivor of Five Points South mass shooting speaks out - Alabama's News Leader
Langley double-shooting kills one, injures another - CityNews Vancouver
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation - Yahoo Finance
One dead, one wounded after 2 men shot in Langley - MSN
Anebulo Pharmaceuticals Secures NIH Grant for Emergency Cannabis Antidote Development - BP Journal
Indian Super League: Anwar Ali cleared to play for East Bengal, say reports - Scroll.in
Anwar Ali receives NOC from AIFFWhen will he make East Bengal debut? - myKhel
Aligos' fatty liver disease treatment meets main goal in mid-stage study - XM
AmaZulu coach Pablo Franco defends Veli Mothwa as Kaizer Chiefs game looms - IOL
Banzai International, Inc. (NASDAQ:BNZI) Sees Large Growth in Short Interest - Defense World
Global X Active Canadian Dividend ETF Common (TSE:HAL) Stock Passes Above 200 Day Moving Average of $20.01 - Defense World
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short Interest - MarketBeat
'Very stupid': Man who helped supply gun later used in Auckland CBD shooting sentenced - New Zealand Herald
Driver arrested in Muse homicide wants assault charge dropped - Bowling Green Daily News
Josue is now a KL City legend - New Straits Times
Scilex Holding (NASDAQ:SCLX) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 5.3% - Defense World
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 8.3% - MarketBeat
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update - Defense World
Anebulo Pharmaceuticals Announces New CEO - GuruFocus.com
Can Actinium Pharmaceuticals (ATNM) bounce back from the Regulatory Hurdles - BP Journal
Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 4% - Defense World
Telehealth Innovations (VSEE) on day when Dow loses more than 750 points - BP Journal
After-Market Stock Rise In Anebulo (ANEB) Indicates Potential Shift In Investor Sentiment - Stocks Telegraph
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Anebulo Pharmaceuticals receives NIDA grant for drug development By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals receives NIDA grant for drug development - Investing.com
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects - Winchester Herald Chronicle
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):